Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 19/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.53 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.53 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.53 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636721 | 0.91 | KRAS (0.67) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL24851022 | 0.87 | KRAS (0.57) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL20109705 | 0.87 | KRAS (0.56) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL20109703 | 0.86 | KRAS (0.44) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128507 | 0.84 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL31658006 | 0.84 | KRAS (0.74) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636866 | 0.82 | KRAS (0.55) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL22880789 | 0.82 | KRAS (0.50) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128492 | 0.81 | KRAS (0.68) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL31657953 | 0.81 | KRAS (0.68) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 262/4885HMOX2 4165/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 365/4885HMOX2 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.